SCHEMBL3967478

SCHEMBL3967478

COC(Cc1ccc(OCC(=O)NCCc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.67
PPARG P37231 7/20 0.66
PPARD Q03181 7/20 0.66
PPARA Q07869 7/20 0.66
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
EPHX2 P34913 3/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
KDM4E B2RXH2 1/20 0.52
LTA4H P09960 2/20 0.51
ABCB1 P08183 1/20 0.51
HPGD P15428 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.51
POLB P06746 2/20 0.51
ALDH1A1 P00352 2/20 0.50
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3967486 1.00 PTPN1 (0.67) PTPN1PPARGPPARDPPARACYP1A2
SCHEMBL6148812 0.94 PTPN1 (0.68) PTPN1PPARGPPARDPPARASMN1; SMN2
SCHEMBL5027065 0.90 PTPN1 (0.72) PTPN1SMN1; SMN2POLBALDH1A1MAPT
SCHEMBL5024521 0.89 PTPN1 (0.60) PTPN1PPARGPPARDPPARASMN1; SMN2
SCHEMBL5024583 0.89 PTPN1 (0.60) PTPN1PPARGPPARDPPARASMN1; SMN2
SCHEMBL5027084 0.89 PTPN1 (0.60) PTPN1PPARGPPARDPPARASMN1; SMN2
SCHEMBL3964790 0.88 PTPN1 (0.59) PTPN1PPARGPPARDPPARASMN1; SMN2
SCHEMBL5360753 0.88 PTPN1 (0.59) PTPN1PPARGPPARDPPARASMN1; SMN2
SCHEMBL3968757 0.84 PPARG (0.69) PPARGPPARDPPARASMN1; SMN2ALDH1A1
SCHEMBL3968762 0.84 PPARG (0.69) PPARGPPARDPPARASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488844-B2 Therapeutic agents ASTRAZENECA AB (SE) 2009-02-10 US claimed
EP-1675820-A2 PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS AstraZeneca AB (SE) 2006-07-05 EP claimed
EP-1676833-A1 Propionic acid derivatives useful in the treatment of lipid disorders AstraZeneca AB (SE) 2006-07-05 EP claimed
US-20050282822-A1 Therapeutic agents ASTRAZENECA AB (SE) 2005-12-22 US claimed
US-20050148656-A1 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes ASTRAZENECA AB (SE) 2005-07-07 US claimed
WO-2004113270-A2 PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS ASTRAZENECA AB (SE) 2004-12-29 WO claimed
US-7488844-B2 Therapeutic agents ASTRAZENECA AB (SE) 2009-02-10 US disclosed
US-20070244198-A1 Carboxylic Derivatives LI LANNA 2007-10-18 US disclosed
US-20060258866-A1 Carboxylic derivates ASTRAZENECA AB, A SWEDEN CORPORATION 2006-11-16 US disclosed
EP-1675820-A2 PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS AstraZeneca AB (SE) 2006-07-05 EP disclosed
EP-1676833-A1 Propionic acid derivatives useful in the treatment of lipid disorders AstraZeneca AB (SE) 2006-07-05 EP disclosed
US-20050282822-A1 Therapeutic agents ASTRAZENECA AB (SE) 2005-12-22 US disclosed
US-20050148656-A1 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes ASTRAZENECA AB (SE) 2005-07-07 US disclosed
WO-2004113270-A2 PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS ASTRAZENECA AB (SE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244198-A1 Carboxylic Derivatives GPR119, CPT1A, PC PTPN1 2707/4885PPARG 56/4885PPARD 84/4885
US-20050148656-A1 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes GPR119, PPARA, PPARG PTPN1 1357/4885PPARG 3/4885PPARD 6/4885
US-20060258866-A1 Carboxylic derivates GPR119, PC, CPT1A PTPN1 2221/4885PPARG 91/4885PPARD 127/4885
US-20050282822-A1 Therapeutic agents GPR119, LIPC, PNLIP PTPN1 2050/4885PPARG 228/4885PPARD 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.